{"nctId":"NCT04697888","briefTitle":"Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease","startDateStruct":{"date":"2013-04","type":"ACTUAL"},"conditions":["Parenteral Nutrition-related Hepatitis"],"count":2,"armGroups":[{"label":"Overall Study","type":"EXPERIMENTAL","interventionNames":["Drug: Omegaven"]}],"interventions":[{"name":"Omegaven","otherNames":["IV Fish Oil Based Lipid Emulsion"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. The patient will be PN dependent and unable to meet nutritional needs solely by enteral nutrition.\n2. Patient will be \\<18 years of age.\n3. Direct bilirubin \\> 2.0mg/dl\n4. The patient must have failed standard therapies to prevent progression his/her liver disease.\n\nExclusion Criteria:\n\n1. Other causes of chronic liver disease (Hepatitis C, Cystic fibrosis, biliary atresia, and alpha 1 anti-trypsin deficiency).\n2. Patients who are allergic to eggs/shellfish\n3. Patients who have severe hemorrhagic disorders.","healthyVolunteers":false,"sex":"ALL","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease Progression as Measured by Serum Levels of Hepatic Enzymes","description":"To evaluate whether established parenteral nutrition associated liver disease (PNALD) can be reversed or its progression halted by using a parenteral fat emulsion prepared from fish oil (omega-3 fatty acid emulsion, OmegavenÂ®) as measured by normalization or decrease of serum levels of hepatic enzymes.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":2},"commonTop":[]}}}